|Selecting an Initial ART Regimen: Lessons From ACTG 5257|
So a person who experienced hyperbilirubinemia and may have thought it a mild cosmetic problem had very little reason not to switch, as opposed to back in the early 2000s when atazanavir came out and there weren't as many good options. So you have ...
Medscape - Fri, 11 Apr 2014 13:25
|Bristol-Myers Squibb Submits New Drug Application to US FDA for a Fixed-Dose ...|
Hyperbilirubinemia: Reversible, asymptomatic elevations in indirect (unconjugated) bilirubin occurred in most patients treated with REYATAZ. There are no long-term safety data for patients with persistent elevations in total bilirubin >5 times upper ...
Business Wire (press release) - Mon, 14 Apr 2014 05:00
|Treatment for Epstein-Barr virus should be tailored at diagnosis|
Patients with hyperbilirubinemia (>1.8 mg/dl) and hyperferritinemia (>20,300 ng/ml) at the time of diagnosis experienced significantly worse outcomes compared with those who had low serum bilirubin and ferritin levels. Sixty-percent of patients were ...
Healio - Mon, 07 Apr 2014 04:15
|Adult dosing regimen of pegaspargase achieves high remission rates|
Dr. Dan Douer of Memorial Sloan-Kettering Cancer Center, New York, and his colleagues reported that there were no pegaspargase-related deaths, with the most common grade three or four toxicities being hyperbilirubinemia (31.3%), transaminitis (62.7%), ...
The Oncology Report - Mon, 31 Mar 2014 11:00
|Exelixis Receives Approval for COMETRIQ® (Cabozantinib) in the European ...|
The most common laboratory abnormalities (≥25%) are increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia. Please see full U.S. ...
PipelineReview.com (press release) - Tue, 25 Mar 2014 09:52
|Exelixis Provides Update on Ongoing COMET-1 Phase 3 Pivotal Trial in Men ...|
The most common laboratory abnormalities (greater-than or equal to 25%) are increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.
MarketWatch - Tue, 25 Mar 2014 16:15